ClinicalTrials.gg
Active, not recruitingNCT06413706Updated Jul 17, 2026

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

A Phase 2 interventional study of Abemaciclib and Temozolomide in Glioma, sponsored by Eli Lilly and Company. Active, not recruiting at 37 sites in 10 countries. Open to participants aged 0 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
0 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Planned enrollment
255th of 737
45 · median 30
Started
2024
with 31 others
Phase 2
227 of 851
21 open now
Primary completion
2027-02
later than 84 of 228 live
Registered
777th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 255th largest by planned enrollment of the 737 interventional ones that give a count, is one of 32 that started in 2024, is one of 227 in phase 2, reaches primary completion later than 84 of the 228 other live ones, and was the 777th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 0 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.

Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.

03

Conditions studied

  • Glioma

Keywords

  • Brain tumor
  • Central nervous system (CNS) tumor
  • Spinal cord tumor
  • Cyclin-dependent kinase (CDK) 4/6 inhibitor
04

Who can participate

Ages eligible
0 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven high-grade glioma (HGG) as defined by 2016 World Health Organization (WHO) Classification Criteria, Grade 3-4 including:
  • Anaplastic astrocytoma
  • Anaplastic ganglioglioma
  • Anaplastic oligodendroglioma.
  • Anaplastic pleomorphic xanthoastrocytoma,
  • Glioblastoma

OR as defined by the 2021 WHO Classification Criteria as molecularly characterized:

  • Non-pontine diffuse midline glioma, H3 K27-altered,
  • Diffuse hemispheric glioma, H3 G34-mutant
  • Diffuse pediatric HGG, H3/IDH-wildtype
  • Infant-type hemispheric glioma
  • High-grade astrocytoma with piloid features
  • High-grade pleomorphic xanthoastrocytoma
  • IDH-mutant diffuse glioma with homozygous cyclin- dependent kinase inhibitor 2A/B (CDKN2A/B) deletion,
  • IDH-mutant and 1p/19q co-deleted oligodendroglioma
  • IDH-mutant astrocytoma with homozygous CDKN2A/B deletion
  • use should be consistent with local regulations for participants in clinical studies.
  • Radiotherapy initiated within 6 weeks (+1 week) of diagnosis and administered over 6 weeks (±1 week). Participants \<3 years of age, considered not suitable for radiotherapy may be eligible.
  • Minimum of 4 weeks between completion of radiation and Cycle 1 Day 1 (C1D1).
  • Maximum of 8 weeks between completion of radiation and C1D1. Exceptional circumstances can be discussed with the medical monitor.
  • Acute effects of prior therapies must be Grade ≤1 unless deemed clinically insignificant by the investigator.
  • Adequate hematologic and organ function ≤7 days prior to C1D1
  • of ≥8 weeks and deemed likely to complete at least 1 cycle of treatment.
  • A performance score of ≥60 using:

    1. Lansky scale for participants \<16 years
    2. scale for participants ≥16 years
  • Able to swallow and/or have a gastric/nasogastric tube.
  • Any current systemic use dose must be stable or decreasing at least 7 days prior to C1D1.
  • Able and willing to adhere to study procedures, including frequent blood draws and MRI.
  • At least 28 days since any major surgery, laparoscopic procedure, or a significant traumatic injury.
  • Has a body surface area (BSA) of ≥0.2 m2.

Exclusion criteria

Exclusion Criteria:

Participants are excluded if any of the following apply:

  • Diffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the pons.
  • Recurrent or HGG including any recurrence/progression during/after radiotherapy.
  • Secondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated .
  • Have known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator.
  • Prior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide).
  • Current enrollment in another trial deemed incompatible with this study.
  • Treatment with an product within the last 30 days or 5 half-lives (whichever is longer).
  • Prior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results.
  • A preexisting medical condition(s) that, per the investigator, would preclude study participation.
  • Any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute or C, or at C1D1.
  • Intolerability or such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome to temozolomide, and/or abemaciclib, their , or dacarbazine.
  • Received a within 28 days of C1D1.
  • Pregnant, breastfeeding, or intend to become pregnant during the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Abemaciclib + Temozolomide - Arm A

    Participants will receive abemaciclib administered orally in addition to temozolomide administered orally or intravenously (IV).

    Drug: Abemaciclib · Drug: Temozolomide

  • Active comparator
    Temozolomide - Arm B

    Participants will receive temozolomide administered orally or IV.

    Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Event Free Survival as Determined by Blinded Independent Review Committee

    Event free survival as determined by blinded independent review committee.

    Time frame: Baseline up to approximately 11 months

Secondary outcomes

  1. Event Free Survival as Determined by Investigator Assessment

    Event free survival as determined by investigator assessment

    Time frame: Baseline up to approximately 11 months

  2. Overall Survival (OS)

    Overall survival

    Time frame: Baseline to date of death due to any cause (up to approximately 18 months)

  3. Overall Response Rate (ORR)

    Overall response rate

    Time frame: Baseline up to approximately 3 months

  4. Disease Control Rate (DCR)

    Disease control rate

    Time frame: Baseline through to disease progression (up to approximately 3 months )

  5. Duration of Response (DoR)

    Duration of response

    Time frame: Date of Complete Response (CR) or Partial Response (PR) or Minor Response (MR) to date of disease progression or death (up to approximately 3 months )

  6. Pharmacokinetic (PK): Abemaciclib Plasma Concentration

    PK Abemaciclib Plasma Concentrations

    Time frame: Cycle 1 through Cycle 4 (21 Day cycle)

  7. Abemaciclib Acceptability and Palatability Questionnaire

    Participants evaluated abemaciclib acceptability (palatability and ease of administration) using a 5-category questionnaire. Participants were asked to select one of the following to describe the acceptability of abemaciclib: Very difficult, difficult, neither easy nor difficult, easy, or very easy.

    Time frame: Day 1 of Cycles 1 through 3 (21 Day Cycles)]

07

Study locations

37 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.

Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Oct 25, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413706
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Oct 25, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion